Efficacy and efficacy E Ef Eff Effi BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
With Moderate-to-Severe with W Wi Wit With BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 -- 2 7 0 0 0 0 1
A Randomized a A A A A BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 0 0 no 0 4 0 0 0 0 1
Andrew Blauvelt, andrew A An And Andr BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 0 ,,;.,,;.,,;,; 13 9 0 0 0 0 1
Marjolein De marjolein M Ma Mar Marj BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 -,;,,;.,;,;,; 13 10 0 0 0 0 1
Tianshuang Wu, tianshuang T Ti Tia Tian BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ,;,,;,,,;.,;, 13 9 0 0 0 0 1
IMPORTANCE Atopic importance I IM IMP IMPO BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 (),, 4 9 0 0 0 0 1
an unmet an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 1 no 0 10 0 0 0 0 1
improvement. improvement. improvement. i im imp impr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 . 1 1 0 0 0 0 1
OBJECTIVE To objective O OB OBJ OBJE BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 10 0 0 0 0 1
moderate-to-severe AD. moderate-to-severe m mo mod mode BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 --. 3 2 0 0 0 0 1
DESIGN, SETTING, design, D DE DES DESI BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 ,,-,--,, 8 9 0 0 0 0 1
multicenter, randomized, multicenter, m mu mul mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 ,,-,-,- 7 9 0 0 0 0 1
comparing the comparing c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 9 0 0 0 0 1
moderate-to-severe AD moderate-to-severe m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 --. 3 9 0 0 0 0 1
from February from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 ,,,, 4 10 0 0 0 0 1
Europe, North europe, E Eu Eur Euro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 ,,,-. 5 9 0 0 0 0 1
were conducted were w we wer were BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 --. 3 5 0 0 0 0 1
INTERVENTIONS Patients interventions I IN INT INTE BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 3 :, 2 10 0 0 0 0 1
daily, or daily, d da dai dail BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ,,. 3 6 0 0 0 0 1
MAIN OUTCOMES main M MA MAI MAIN BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 4 (). 3 8 0 0 0 0 1
percentage change percentage p pe per perc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 ()( 3 9 0 0 0 0 1
average), proportion average), a av ave aver BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 ),, 3 9 0 0 0 0 1
from baseline from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 , 1 10 0 0 0 0 1
2, percentage 2, 2 2, 2, 2, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 4 ,(), 4 10 0 0 0 0 1
Pruritus NRS pruritus P Pr Pru Prur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 4 (). 3 9 0 0 0 0 1
24 included 24 2 24 24 24 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 0 4 ,,, 3 9 0 0 0 0 1
NRS from nrs N NR NRS NRS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 4 ().- 4 9 0 0 0 0 1
in all in i in in in BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 4 . 1 6 0 0 0 0 1
RESULTS Of results R RE RES RESU BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 0 6 ,([.];[],.[.]) 14 9 0 0 0 0 1
were randomized were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 9 0 0 0 0 1
(194 men (194 ( (1 (19 (194 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 6 ([.];[],.[.]); 14 10 0 0 0 0 1
were balanced were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ., 2 9 0 0 0 0 1
(71.0%) and (71.0%) ( (7 (71 (71. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 6 (.)(.)(.). 10 9 0 0 0 0 1
secondary end secondary s se sec seco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 , 1 9 0 0 0 0 1
including improvement including i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ([],.[.] 8 9 0 0 0 0 1
8.8% [1.8%]; 8.8% 8 8. 8.8 8.8% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 6 .[.];.),([.][.]; 16 10 0 0 0 0 1
P < p P P P P BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 6 .),([.][.];.). 14 9 0 0 0 0 1
of serious of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ,,,- 4 9 0 0 0 0 1
events were events e ev eve even BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 6 , 1 9 0 0 0 0 1
and injection-site and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 -. 2 8 0 0 0 0 1
CONCLUSIONS AND conclusions C CO CON CONC BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 , 1 9 0 0 0 0 1
superior efficacy superior s su sup supe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 --, 3 10 0 0 0 0 1
signals. signals. signals. s si sig sign BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 . 1 1 0 0 0 0 1
TRIAL REGISTRATION trial T TR TRI TRIA BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 0 10 .: 2 10 0 0 0 0 1
JAMA Dermatol. jama J JA JAM JAMA BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 0 10 .;():-.:./.. 12 10 0 1 0 0 1
Published online published P Pu Pub Publ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 ,.,. 4 8 0 1 0 0 1
Visual Abstract visual V Vi Vis Visu BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 no 0 10 0 0 0 0 1
Supplemental content supplemental S Su Sup Supp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 no 0 10 0 0 0 0 1
CME Quiz cme C CM CME CME BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 no 0 4 0 0 0 0 1
jamacmelookup.com and jamacmelookup.com j ja jam jama BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 10 . 1 10 0 0 0 0 1
Questions page questions Q Qu Que Ques BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 no 0 7 0 0 0 0 1
Author Affiliations: author A Au Aut Auth BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 : 1 6 0 0 0 0 1
affiliations are affiliations a af aff affi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 no 0 10 0 0 0 0 1
article. article. article. a ar art arti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 . 1 2 0 0 0 0 1
Corresponding Author: corresponding C Co Cor Corr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 11 : 1 8 0 0 0 0 1
Blauvelt, MD, blauvelt, B Bl Bla Blau BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 ,,, 3 9 0 0 0 0 1
Research Center, research R Re Res Rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 11 ,, 2 10 0 0 0 0 1
Suite G, suite S Su Sui Suit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 11 ,, 2 7 0 0 0 0 1
(ablauvelt@oregonmedicalresearch. (ablauvelt@oregonmedicalresearch. (ablauvelt@oregonmedicalresearch. ( (a (ab (abl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 11 (@. 3 9 0 0 0 0 1
com). com). com). c co com com) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 11 ). 2 1 0 0 0 0 1
Research Research research R Re Res Rese BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 11 no 0 10 0 1 0 0 0
JAMA Dermatology jama J JA JAM JAMA BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 0 11 no 0 10 0 1 0 0 1
(Reprinted) 1047 (reprinted) ( (R (Re (Rep BLOCKSTART PAGEIN SAMEFONT LOWERFONT 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 11 () 2 10 0 1 0 0 0
Downloaded From: downloaded D Do Dow Down BLOCKSTART PAGEEND NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 :://./// 8 10 0 1 1 1 0
A A a A A A A BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 1 0 no 0 10 0 0 0 0 1
topic dermatitis topic t to top topi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 () 2 8 0 0 0 0 1
relapsing nature, relapsing r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,, 2 7 0 0 0 0 1
pruritus. 1,2 pruritus. p pr pru prur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 .,, 3 8 0 0 0 0 1
such as such s su suc such BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 (-),-,-,-, 10 10 0 0 0 0 1
(IFN-γ), and (ifn-γ), ( (I (IF (IFN BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 (-),(),- 8 8 0 0 0 0 1
duce signals duce d du duc duce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 -- 2 9 0 0 0 0 1
tor of tor t to tor tor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 (-).,, 6 9 0 0 0 0 1
a fully a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
IL-4 receptor il-4 I IL IL- IL-4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 0 ---, 4 9 0 0 0 0 1
for the for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 --;, 4 9 0 0 0 0 1
half of half h ha hal half BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
of dupilumab of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 8 0 0 0 0 1
after week after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ., 2 9 0 0 0 0 1
options that options o op opt opti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
proportion of proportion p pr pro prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 7 0 0 0 0 1
Upadacitinib is upadacitinib U Up Upa Upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 ,,- 3 8 0 0 0 0 1
hibitor engineered hibitor h hi hib hibi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
JAK3, and jak3, J JA JAK JAK3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 0 ,,- 3 9 0 0 0 0 1
ficacy and ficacy f fi fic fica BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
with other, with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,-.- 4 9 0 0 0 0 1
proved in proved p pr pro prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,,- 3 8 0 0 0 0 1
tries to tries t tr tri trie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
tis, and tis, t ti tis tis, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
immune-mediated inflammatory immune-mediated i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -. 2 9 0 0 0 0 1
2b 7 2b 2 2b 2b 2b BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 0 (, 2 9 0 0 0 0 1
Up 2, up U Up Up Up BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 ,),- 4 9 0 0 0 0 1
(15 or (15 ( (1 (15 (15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 0 ()- 3 9 0 0 0 0 1
for patients for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 --., 4 8 0 0 0 0 1
safety and safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
moderate-to-severe AD. moderate-to-severe m mo mod mode BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 --. 3 3 0 0 0 0 1
Methods Methods methods M Me Met Meth BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 10 0 0 0 0 1
Study Design study S St Stu Stud BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 10 0 0 0 0 1
Heads Up heads H He Hea Head BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 ()-,--, 7 8 0 0 0 0 1
3b, multicenter, 3b, 3 3b 3b, 3b, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 3 ,,,-,-, 7 8 0 0 0 0 1
active-controlled clinical active-controlled a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 - 1 10 0 0 0 0 1
of upadacitinib of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 -- 2 8 0 0 0 0 1
severe AD. severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 ., 2 9 0 0 0 0 1
2019, to 2019, 2 20 201 2019 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 1 3 ,,, 3 9 0 0 0 0 1
across Europe, across a ac acr acro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 ,,,- 4 9 0 0 0 0 1
Pacific region. pacific P Pa Pac Paci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 .-,- 4 9 0 0 0 0 1
week double-blinded week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 -,-- 4 9 0 0 0 0 1
visit or visit v vi vis visi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 - 1 9 0 0 0 0 1
study. Independent study. s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 . 1 9 0 0 0 0 1
boards approved boards b bo boa boar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 ,(), 4 9 0 0 0 0 1
and recruitment and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 . 1 10 0 0 0 0 1
trial was trial t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 3 no 0 9 0 0 0 0 1
for Harmonisation for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 ,, 2 9 0 0 0 0 1
Declaration of declaration D De Dec Decl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 . 1 9 0 0 0 0 1
consent before consent c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 . 1 9 0 0 0 0 1
Standards of standards S St Sta Stan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 3 ()( 3 9 0 0 0 0 1
in Supplement in i in in in BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 3 ). 2 2 0 0 0 0 1
Patients Patients patients P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 10 0 1 0 0 1
Eligible patients eligible E El Eli Elig BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 - 1 9 0 1 0 0 1
nosed AD nosed n no nos nose BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 - 1 10 0 1 0 0 1
didates for didates d di did dida BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 6 ( 1 9 0 0 0 0 1
treatments for treatments t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 , 1 9 0 0 0 0 1
AD, or ad, A AD AD, AD, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 6 ,- 2 9 0 0 0 0 1
able) and able) a ab abl able BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 6 )--( 4 9 0 0 0 0 1
≥10% of ≥10% ≥ ≥1 ≥10 ≥10% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 6 , 1 9 0 0 0 0 1
Severity Index severity S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 6 [],'- 5 9 0 0 0 0 1
sessment for sessment s se ses sess BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 6 , 1 10 0 0 0 0 1
weekly average weekly w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 [] 2 9 0 0 0 0 1
score ≥4 score s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 ).- 3 9 0 0 0 0 1
umab was umab u um uma umab BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 6 . 1 9 0 0 0 0 1
patient eligibility patient p pa pat pati BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 . 1 4 0 0 0 0 1
Clinical Trial clinical C Cl Cli Clin BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 7 no 0 10 0 0 0 0 1
Patients were patients P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 7 :- 2 9 0 0 0 0 1
tinib via tinib t ti tin tini BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 7 - 1 9 0 0 0 0 1
daily until daily d da dai dail BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 7 no 0 9 0 0 0 0 1
a subcutaneous a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 1 7 no 0 9 0 0 0 0 1
of 600 of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 7 ,( 2 10 0 0 0 0 1
Supplement 2). supplement S Su Sup Supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 7 )., 3 9 0 0 0 0 1
systemic immunomodulatory systemic s sy sys syst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 7 , 1 8 0 0 0 0 1
could be could c co cou coul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 7 . 1 9 0 0 0 0 1
Patients who patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 7 - 1 9 0 0 0 0 1
responders for responders r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 7 no 0 9 0 0 0 0 1
rescue therapy. rescue r re res resc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 7 . 1 2 0 0 0 0 1
Efficacy Parameters efficacy E Ef Eff Effi BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 no 0 10 0 0 0 0 1
Efficacy was efficacy E Ef Eff Effi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 no 0 9 0 0 0 0 1
with dupilumab, with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 ,- 2 8 0 0 0 0 1
provement in provement p pr pro prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 (). 3 9 0 0 0 0 1
points were: points p po poi poin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 :- 2 9 0 0 0 0 1
tus NRS, tus t tu tus tus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 ,,- 3 9 0 0 0 0 1
centage change centage c ce cen cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 no 0 9 0 0 0 0 1
4, achievement 4, 4 4, 4, 4, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 8 ,, 2 9 0 0 0 0 1
baseline in baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 , 1 9 0 0 0 0 1
NRS improvement nrs N NR NRS NRS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 . 1 9 0 0 0 0 1
unranked end unranked u un unr unra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 , 1 8 0 0 0 0 1
achievement of achievement a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 ,,,- 4 9 0 0 0 0 1
provement of provement p pr pro prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 . 1 10 0 0 0 0 1
Pruritus NRS pruritus P Pr Pru Prur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 no 0 10 0 0 0 0 1
pruritus scores. pruritus p pr pru prur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 .- 2 9 0 0 0 0 1
Oriented Eczema oriented O Or Ori Orie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 - 1 9 0 0 0 0 1
line in line l li lin line BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 . 1 3 0 0 0 0 1
Key Points key K Ke Key Key BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 2 10 no 0 10 0 1 0 0 1
Question Are question Q Qu Que Ques BLOCKSTART PAGEIN SAMEFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 10 no 0 10 0 0 0 0 1
to subcutaneous to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 -- 2 8 0 0 0 0 1
atopic dermatitis atopic a at ato atop BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 10 ()? 3 3 0 0 0 0 1
Findings This findings F Fi Fin Find BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 10 ,,-- 4 8 0 0 0 0 1
clinical trial clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 -- 2 8 0 0 0 0 1
demonstrated clinically demonstrated d de dem demo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 , 1 9 0 0 0 0 1
with statistically with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 no 0 10 0 0 0 0 1
with dupilumab. with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 . 1 8 0 0 0 0 1
either upadacitinib either e ei eit eith BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 . 1 4 0 0 0 0 1
Meaning Upadacitinib meaning M Me Mea Mean BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 11 no 0 9 0 0 0 0 1
clearance and clearance c cl cle clea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 11 no 0 10 0 0 0 0 1
dupilumab in dupilumab d du dup dupi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 11 --. 3 8 0 0 0 0 1
Research Original research R Re Res Rese BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 2 11 no 0 4 0 1 0 0 0
Upadacitinib vs upadacitinib U Up Upa Upad BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 11 -- 2 10 0 1 0 0 0
1048 1048 1048 1 10 104 1048 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 2 11 no 0 0 0 1 0 0 0
JAMA Dermatology jama J JA JAM JAMA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 2 11 ,() 3 10 0 1 0 0 0
jamadermatology.com jamadermatology.com jamadermatology.com j ja jam jama BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 11 . 1 3 0 1 0 0 0
Downloaded From: downloaded D Do Dow Down BLOCKSTART PAGEEND NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 11 :://./// 8 10 0 1 1 0 0
Safety Parameters safety S Sa Saf Safe BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 10 0 1 0 0 1
Safety was safety S Sa Saf Safe BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 9 0 0 0 0 1
(TEAEs) in (teaes) ( (T (TE (TEA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 () 2 9 0 0 0 0 1
drug through drug d dr dru drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -(- 3 9 0 0 0 0 1
dacitinib or dacitinib d da dac daci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ); 2 10 0 0 0 0 1
was defined was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 () 2 9 0 0 0 0 1
in severity in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 0 . 1 10 0 0 0 0 1
AEs presented aes A AE AEs AEs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 -, 2 8 0 0 0 0 1
noted. noted. noted. n no not note BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 . 1 1 0 0 0 0 1
Statistical Analysis statistical S St Sta Stat BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 10 0 0 0 0 1
Statistical analysis statistical S St Sta Stat BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 --. 3 9 0 0 0 0 1
The primary the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
NRI-C (Nonresponder nri-c N NR NRI NRI- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 -(- 3 8 0 0 0 0 1
putation [MI] putation p pu put puta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 []-). 5 8 0 0 0 0 1
initial NRI initial i in ini init BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 8 0 0 0 0 1
COVID-19 pandemic, covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 -, 2 8 0 0 0 0 1
to logistical to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 ;- 2 9 0 0 0 0 1
approach are approach a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 .- 2 8 0 0 0 0 1
tiplicity-adjusted results tiplicity-adjusted t ti tip tipl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 -- 2 9 0 0 0 0 1
ing procedure, ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 2 0 ,- 2 10 0 0 0 0 1
mary and mary m ma mar mary BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 2 0 -. 2 9 0 0 0 0 1
(eFigure 2 (efigure ( (e (eF (eFi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 (). 3 4 0 0 0 0 1
Results Results results R Re Res Resu BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 2 2 no 0 10 0 0 0 0 1
Patient Disposition patient P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 2 no 0 10 0 0 0 0 1
A total a A A A A BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 2 2 ,- 2 9 0 0 0 0 1
cluded and cluded c cl clu clud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 ;([.]; 6 9 0 0 0 0 1
mean [SD] mean m me mea mean BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 [],.[.]), 9 10 0 0 0 0 1
(194 men (194 ( (1 (19 (194 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 2 ([.];[],.[.])- 14 9 0 0 0 0 1
pilumab. The pilumab. p pi pil pilu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 . 1 9 0 0 0 0 1
was low was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 ;(.)- 5 8 0 0 0 0 1
ment, and ment, m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 ,(.) 4 8 0 0 0 0 1
(Figure 1); (figure ( (F (Fi (Fig BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 ();(.)- 7 9 0 0 0 0 1
tinib treatment, tinib t ti tin tini BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 ,(.) 4 9 0 0 0 0 1
of dupilumab of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 .--- 4 9 0 0 0 0 1
tients (25.0%) tients t ti tie tien BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 (.)-(.)- 8 9 0 0 0 0 1
ceived rescue ceived c ce cei ceiv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 no 0 9 0 0 0 0 1
visits after visits v vi vis visi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 . 1 6 0 0 0 0 1
Demographic and demographic D De Dem Demo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 2 no 0 8 0 0 0 0 1
among the among a am amo amon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 -- 2 8 0 0 0 0 1
groups, including groups, g gr gro grou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 ,:() 4 9 0 0 0 0 1
EASI (30.8 easi E EA EAS EASI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 2 (.[.].[.],) 11 9 0 0 0 0 1
of patients of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 '- 2 9 0 0 0 0 1
ment for ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 ([.][.],) 9 8 0 0 0 0 1
(Table 1). (table ( (T (Ta (Tab BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 (). 3 1 0 0 0 0 1
Efficacy Outcomes efficacy E Ef Eff Effi BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 10 0 0 0 0 1
The proportion the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 9 0 0 0 0 1
was significantly was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 10 0 0 0 0 1
than those than t th tha than BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ([.][.]; 8 9 0 0 0 0 1
adjusted difference, adjusted a ad adj adju BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ,.(,.-.;.) 10 9 0 0 0 0 1
(Table 2), (table ( (T (Ta (Tab BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 (), 3 10 0 0 0 0 1
week 16 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 - 1 9 0 0 0 0 1
umab. The umab. u um uma umab BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 .- 2 8 0 0 0 0 1
approach. The approach. a ap app appr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 .- 2 9 0 0 0 0 1
those based those t th tho thos BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 -(), 4 9 0 0 0 0 1
that the that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 8 0 0 0 0 1
COVID-19 for covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 -(.[]) 6 9 0 0 0 0 1
(eTables 2 (etables ( (e (eT (eTa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 (). 3 8 0 0 0 0 1
treatment groups treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 ( 1 9 0 0 0 0 1
Supplement 2). supplement S Su Sup Supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 ). 2 2 0 0 0 0 1
Onset of onset O On Ons Onse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 , 1 9 0 0 0 0 1
proportion of proportion p pr pro prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 - 1 9 0 0 0 0 1
cantly greater cantly c ca can cant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 no 0 9 0 0 0 0 1
those receiving those t th tho thos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 ([.] 4 9 0 0 0 0 1
[17.4%]; P [17.4%]; [ [1 [17 [17. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 [.];.)(). 9 10 0 0 0 0 1
of patients of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 ( 1 8 0 0 0 0 1
EASI100) at easi100) E EA EAS EASI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 )- 2 8 0 0 0 0 1
lumab (EASI90, lumab l lu lum luma BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 (,[.][.];.;, 12 9 0 0 0 0 1
97 [27.9%] 97 9 97 97 97 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 5 [.][.];.).() 12 9 0 0 0 0 1
improvement from improvement i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 - 1 8 0 0 0 0 1
cantly greater cantly c ca can cant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 - 1 9 0 0 0 0 1
dupilumab-treated patients dupilumab-treated d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 -(.[.] 6 9 0 0 0 0 1
8.8% [1.8%]; 8.8% 8 8. 8.8 8.8% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 .[.];.)(.[.]. 13 8 0 0 0 0 1
[2.2%]; P [2.2%]; [ [2 [2. [2.2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 [.];.),- 8 8 0 0 0 0 1
tained through tained t ta tai tain BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 (.[.].[.]; 10 8 0 0 0 0 1
P < p P P P P BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 3 5 .)., 4 9 0 0 0 0 1
a clinically a a a a a BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 3 5 ( 1 9 0 0 0 0 1
Figure 1. figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 9 . 1 10 0 1 0 0 1
924 Patients 924 9 92 924 924 BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
via physical via v vi via via BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 9 no 0 6 0 0 0 0 1
232 Excluded 232 2 23 232 232 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
692 Patients 692 6 69 692 692 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
344 Assigned 344 3 34 344 344 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 7 0 0 0 0 1
344 Treated 344 3 34 344 344 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
70 Received 70 7 70 70 70 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 8 0 0 0 0 1
before week before b be bef befo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 9 no 0 4 0 0 0 0 1
348 Assigned 348 3 34 348 348 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 8 0 0 0 0 1
348 Treated 348 3 34 348 348 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
61 Received 61 6 61 61 61 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 8 0 0 0 0 1
before week before b be bef befo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 9 no 0 4 0 0 0 0 1
328 Completed 328 3 32 328 328 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 8 0 0 0 0 1
through week through t th thr thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 9 no 0 5 0 0 0 0 1
15 Received 15 1 15 15 15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
after week after a af aft afte BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 9 no 0 4 0 0 0 0 1
336 Completed 336 3 33 336 336 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 8 0 0 0 0 1
through week through t th thr thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 9 no 0 5 0 0 0 0 1
27 Received 27 2 27 27 27 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
after week after a af aft afte BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 9 no 0 4 0 0 0 0 1
319 Completed 319 3 31 319 319 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
week 24 week w we wee week BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 2 0 0 0 0 1
316 Completed 316 3 31 316 316 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
week 24 week w we wee week BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 2 0 0 0 0 1
16 Discontinued 16 1 16 16 16 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
2 Adverse 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 6 0 0 0 0 1
7 Withdrew 7 7 7 7 7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 7 0 0 0 0 1
4 Lost 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 - 1 7 0 0 0 0 1
3 Other 3 3 3 3 3 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 3 0 0 0 0 1
9 Discontinued 9 9 9 9 9 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
2 Adverse 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 6 0 0 0 0 1
3 Lack 3 3 3 3 3 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
1 Withdrew 1 1 1 1 1 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 9 0 0 0 0 1
1 Lost 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 - 1 10 0 0 0 0 1
2 Other 2 2 2 2 2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
20 Discontinued 20 2 20 20 20 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
7 Adverse 7 7 7 7 7 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 6 0 0 0 0 1
6 Lack 6 6 6 6 6 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
3 Withdrew 3 3 3 3 3 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 9 0 0 0 0 1
3 Lost 3 3 3 3 3 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 - 1 10 0 0 0 0 1
1 Other 1 1 1 1 1 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
12 Discontinued 12 1 12 12 12 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
3 Adverse 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 6 0 0 0 0 1
5 Withdrew 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 7 0 0 0 0 1
1 Lost 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 - 1 7 0 0 0 0 1
1 COVID-19 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 - 1 8 0 0 0 0 1
2 Other 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 10 no 0 3 0 0 0 0 1
CONSORT diagram consort C CO CON CONS BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 11 ,,. 3 9 0 0 0 0 1
The primary the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 . 1 10 0 0 0 0 1
Severity Index. severity S Se Sev Seve BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 . 1 1 0 0 0 0 1
Upadacitinib vs upadacitinib U Up Upa Upad BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 11 -- 2 10 0 1 0 0 0
Original Investigation original O Or Ori Orig BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 no 0 4 0 1 0 0 0
jamadermatology.com jamadermatology.com jamadermatology.com j ja jam jama BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 11 . 1 3 0 1 0 0 0
(Reprinted) JAMA (reprinted) ( (R (Re (Rep BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 11 (), 3 10 0 1 0 0 0
1049 1049 1049 1 10 104 1049 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 3 11 no 0 0 0 1 0 0 0
Downloaded From: downloaded D Do Dow Down BLOCKSTART PAGEEND NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 11 :://./// 8 10 0 1 1 0 0
NRS improvement nrs N NR NRS NRS BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 ) 1 8 0 0 0 0 1
higher for higher h hi hig high BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 8 0 0 0 0 1
those who those t th tho thos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ([.] 4 8 0 0 0 0 1
336 [35.7%]; 336 3 33 336 336 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 0 [.];.).,- 9 8 0 0 0 0 1
ondary efficacy ondary o on ond onda BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ,- 2 8 0 0 0 0 1
tinib achieved tinib t ti tin tini BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 no 0 8 0 0 0 0 1
investigator-and patient-reported investigator-and i in inv inve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 -- 2 8 0 0 0 0 1
dupilumab. dupilumab. dupilumab. d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 . 1 1 0 0 0 0 1
Numerically greater numerically N Nu Num Nume BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 - 1 8 0 0 0 0 1
dupilumab-treated patients dupilumab-treated d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 - 1 9 0 0 0 0 1
(55 of (55 ( (5 (55 (55 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 0 ([.][.])( 9 9 0 0 0 0 1
[69.9%] vs [69.9%] [ [6 [69 [69. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 0 [.][.])(). 10 9 0 0 0 0 1
were observed were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ( 1 9 0 0 0 0 1
[18.5%] vs [18.5%] [ [1 [18 [18. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 0 [.][.])([.] 11 9 0 0 0 0 1
of 344 of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 [.])().- 8 9 0 0 0 0 1
tions of tions t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 -- 2 9 0 0 0 0 1
achievement of achievement a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ( 1 9 0 0 0 0 1
[8.3%] vs [8.3%] [ [8 [8. [8.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 0 [.][.])( 8 9 0 0 0 0 1
of 348 of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 [.][.])()., 11 9 0 0 0 0 1
upadacitinib-treated patients upadacitinib-treated u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 - 1 10 0 0 0 0 1
than dupilumab-treated than t th tha than BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 -() 3 9 0 0 0 0 1
as early as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (−.[.]−.[.]) 12 9 0 0 0 0 1
through week through t th thr thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (−.[.]−.[.])(). 15 9 0 0 0 0 1
A greater a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 3 0 -- 2 8 0 0 0 0 1
treated patients treated t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ([.] 4 9 0 0 0 0 1
344 [59.5%]; 344 3 34 344 344 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 2 [.];.- 6 9 0 0 0 0 1
justment for justment j ju jus just BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 2 )(). 4 9 0 0 0 0 1
In addition, in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 2 , 1 8 0 0 0 0 1
upadacitinib-treated patients upadacitinib-treated u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 2 -(.) 4 9 0 0 0 0 1
at week at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 -(.), 5 9 0 0 0 0 1
while EASI90 while w wh whi whil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 - 1 9 0 0 0 0 1
treated patients treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 (.;. 4 9 0 0 0 0 1
without adjustment without w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 ) 1 9 0 0 0 0 1
at week at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 -(.; 4 9 0 0 0 0 1
.001 for .001 . .0 .00 .001 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 2 .- 2 9 0 0 0 0 1
tiplicity). Upadacitinib-treated tiplicity). t ti tip tipl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 2 ).-- 4 10 0 0 0 0 1
ment from ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 2 () 2 8 0 0 0 0 1
dupilumab-treated patients dupilumab-treated d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 2 -(.[.]. 7 9 0 0 0 0 1
[2.8%]; P [2.8%]; [ [2 [2. [2.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 2 [.];. 5 9 0 0 0 0 1
for multiplicity). for f fo for for BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 ). 2 2 0 0 0 0 1
Safety Outcomes safety S Sa Saf Safe BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 10 0 0 0 0 1
The safety the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 9 0 0 0 0 1
with that with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 - 1 9 0 0 0 0 1
cal trials cal c ca cal cal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 4 4 (,,),(). 8 10 0 0 0 0 1
No new no N No No No BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 9 0 0 0 0 1
study compared study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 .-- 3 8 0 0 0 0 1
dence rates dence d de den denc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 .-- 3 8 0 0 0 0 1
tients (249 tients t ti tie tien BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ().- 4 9 0 0 0 0 1
(216 of (216 ( (2 (21 (216 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 (). 3 9 0 0 0 0 1
study drug study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 .().( 5 9 0 0 0 0 1
of 348) of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ).().() 7 9 0 0 0 0 1
for dupilumab, for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ,.- 3 8 0 0 0 0 1
associated bronchopneumonia associated a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 -- 2 8 0 0 0 0 1
upadacitinib-treated patient. upadacitinib-treated u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 -. 2 4 0 0 0 0 1
Through 16 through T Th Thr Thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 ,- 2 8 0 0 0 0 1
ported AE ported p po por port BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 no 0 9 0 0 0 0 1
(55 [15.8%]), (55 ( (5 (55 (55 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 ([.]), 6 9 0 0 0 0 1
with dupilumab with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 (.)(). 6 9 0 0 0 0 1
moderate in moderate m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ,, 2 9 0 0 0 0 1
did not did d di did did BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ;- 2 9 0 0 0 0 1
tion. The tion. t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 . 1 9 0 0 0 0 1
with dupilumab with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ([.]),- 7 8 0 0 0 0 1
junctivitis was junctivitis j ju jun junc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 no 0 9 0 0 0 0 1
(1.4%). All (1.4%). ( (1 (1. (1.4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 (.).- 5 9 0 0 0 0 1
ity, and ity, i it ity ity, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ,. 2 7 0 0 0 0 1
Among AEs among A Am Amo Amon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 ,( 2 9 0 0 0 0 1
[1.1%] vs [1.1%] [ [1 [1. [1.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 [.][.]),([.]),- 15 9 0 0 0 0 1
pes zoster pes p pe pes pes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ([.][.])- 9 9 0 0 0 0 1
tients treated tients t ti tie tien BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 no 0 8 0 0 0 0 1
dupilumab, all dupilumab, d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ,().- 5 9 0 0 0 0 1
rious infections rious r ri rio riou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 .- 2 9 0 0 0 0 1
peticum or peticum p pe pet peti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 . 1 9 0 0 0 0 1
herpes zoster herpes h he her herp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 , 1 9 0 0 0 0 1
led to led l le led led BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 .- 2 9 0 0 0 0 1
volved a volved v vo vol volv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ; 1 9 0 0 0 0 1
or more or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ,(- 3 8 0 0 0 0 1
orbital skin) orbital o or orb orbi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ). 2 6 0 0 0 0 1
The rate the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 8 0 0 0 0 1
treated with treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 - 1 8 0 0 0 0 1
umab (10 umab u um uma umab BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ([.][.])(). 11 9 0 0 0 0 1
disorders were disorders d di dis diso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 8 0 0 0 0 1
moderate in moderate m mo mod mode BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ,, 2 8 0 0 0 0 1
Table 1. table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 . 1 10 0 1 0 0 1
Characteristic Characteristic characteristic C Ch Cha Char BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 10 0 0 0 0 1
Patients, No. patients, P Pa Pat Pati BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 ,.() 4 10 0 1 0 0 1
Dupilumab, 300 dupilumab, D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 8 , 1 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 8 () 2 5 0 0 0 0 1
Upadacitinib, 30 upadacitinib, U Up Upa Upad BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 8 , 1 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 8 () 2 5 0 0 0 0 1
Sex Sex sex S Se Sex Sex BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 10 0 0 0 0 1
Male Male male M Ma Mal Male BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 4 0 0 0 0 1
194 (56.4) 194 1 19 194 194 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 8 (.) 3 10 0 0 0 0 1
183 (52.6) 183 1 18 183 183 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 8 (.) 3 10 0 0 0 0 1
Female Female female F Fe Fem Fema BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 no 0 6 0 0 0 0 1
150 (43.6) 150 1 15 150 150 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 10 0 0 0 0 1
165 (47.4) 165 1 16 165 165 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 10 0 0 0 0 1
Age, mean age, A Ag Age Age, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 ,()[], 6 10 0 0 0 0 1
36.9 (14.09) 36.9 3 36 36. 36.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(.) 4 5 0 0 0 0 1
[18-76] [18-76] [18-76] [ [1 [18 [18- BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 [-] 3 3 0 0 0 0 1
36.6 (14.61) 36.6 3 36 36. 36.6 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(.)[-] 7 10 0 0 0 0 1
Age group, age A Ag Age Age BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 , 1 10 0 0 0 0 1
<40 <40 <40 < <4 <40 <40 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 no 0 3 0 0 0 0 1
226 (65.7) 226 2 22 226 226 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 10 0 0 0 0 1
228 (65.5) 228 2 22 228 228 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 10 0 0 0 0 1
≥40 to ≥40 ≥ ≥4 ≥40 ≥40 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 no 0 10 0 0 0 0 1
101 (29.4) 101 1 10 101 101 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 10 0 0 0 0 1
102 (29.3) 102 1 10 102 102 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 10 0 0 0 0 1
≥65 ≥65 ≥65 ≥ ≥6 ≥65 ≥65 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 no 0 4 0 0 0 0 1
17 (4.9) 17 1 17 17 17 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 10 0 0 0 0 1
18 (5.2) 18 1 18 18 18 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 10 0 0 0 0 1
Disease duration disease D Di Dis Dise BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 no 0 9 0 0 0 0 1
diagnosis, mean diagnosis, d di dia diag BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 ,(), 4 10 0 0 0 0 1
25.0 (14.8) 25.0 2 25 25. 25.0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(.) 4 10 0 0 0 0 1
23.5 (14.7) 23.5 2 23 23. 23.5 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(.) 4 10 0 0 0 0 1
Weight, mean weight, W We Wei Weig BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 ,(), 4 10 0 0 0 0 1
75.6 (18.4) 75.6 7 75 75. 75.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(.) 4 5 0 0 0 0 1
78.8 (22.3) 78.8 7 78 78. 78.8 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(.) 4 5 0 0 0 0 1
BMI, mean bmi, B BM BMI BMI, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 ,() 3 10 0 0 0 0 1
25.99 (5.72) 25.99 2 25 25. 25.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 8 0 0 0 0 1
26.99 (6.53) 26.99 2 26 26. 26.9 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 10 0 0 0 0 1
BSA, mean bsa, B BS BSA BSA, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 ,(), 4 10 0 0 0 0 1
44.4 (22.8) 44.4 4 44 44. 44.4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 6 0 0 0 0 1
48.2 (24.0) 48.2 4 48 48. 48.2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 6 0 0 0 0 1
vIGA-AD score viga-ad v vI vIG vIGA BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 - 1 10 0 0 0 0 1
3 (Moderate) 3 3 3 3 3 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 10 () 2 10 0 0 0 0 1
171 (49.7) 171 1 17 171 171 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 10 (.) 3 8 0 0 0 0 1
174 (50.0) 174 1 17 174 174 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 10 (.) 3 8 0 0 0 0 1
4 (Severe) 4 4 4 4 4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 10 () 2 10 0 0 0 0 1
173 (50.3) 173 1 17 173 173 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 10 (.) 3 10 0 0 0 0 1
174 (50.0) 174 1 17 174 174 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 10 (.) 3 10 0 0 0 0 1
EASI, mean easi, E EA EAS EASI BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 ,() 3 10 0 0 0 0 1
28.8 (11.5) 28.8 2 28 28. 28.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 7 0 0 0 0 1
30.8 (12.5) 30.8 3 30 30. 30.8 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 7 0 0 0 0 1
Worst Pruritus worst W Wo Wor Wors BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 10 [ 1 10 0 0 0 0 1
average], mean average], a av ave aver BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 ],() 4 7 0 0 0 0 1
7.5 (1.7) 7.5 7 7. 7.5 7.5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 10 0 0 0 0 1
7.4 (1.6) 7.4 7 7. 7.4 7.4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 10 0 0 0 0 1
Abbreviations: BMI, abbreviations: A Ab Abb Abbr BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 :,( 3 10 0 0 0 0 1
by height by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 11 );,;, 5 9 0 0 0 0 1
Severity Index; severity S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 ;,;-,' 6 10 0 0 0 0 1
Global Assessment. global G Gl Glo Glob BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 . 1 2 0 0 0 0 1
a Baseline a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 5 11 no 0 9 0 0 0 0 1
Heads Up heads H He Hea Head BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 (-). 4 3 0 0 0 0 1
b Data b b b b b BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 5 11 . 1 3 0 0 0 0 1
Research Original research R Re Res Rese BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 11 no 0 4 0 1 0 0 0
Upadacitinib vs upadacitinib U Up Upa Upad BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 11 -- 2 10 0 1 0 0 0
1050 1050 1050 1 10 105 1050 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 5 11 no 0 0 0 1 0 0 0
JAMA Dermatology jama J JA JAM JAMA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 5 11 ,() 3 10 0 1 0 0 0
jamadermatology.com jamadermatology.com jamadermatology.com j ja jam jama BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 11 . 1 3 0 1 0 0 0
Downloaded From: downloaded D Do Dow Down BLOCKSTART PAGEEND NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 11 :://./// 8 10 0 1 1 0 0
abnormalities without abnormalities a ab abn abno BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ;, 2 9 0 0 0 0 1
upadacitinib-treated patients upadacitinib-treated u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 - 1 8 0 0 0 0 1
owing to owing o ow owi owin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 .([.] 5 9 0 0 0 0 1
vs 1 vs v vs vs vs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 [.]),([.][.]),- 15 10 0 0 0 0 1
nine phosphokinase nine n ni nin nine BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ([.][.]) 8 9 0 0 0 0 1
were higher were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
those treated those t th tho thos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,. 2 9 0 0 0 0 1
single event single s si sin sing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 () 2 9 0 0 0 0 1
reported in reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 9 0 0 0 0 1
these laboratory these t th the thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 9 0 0 0 0 1
severity, transient, severity, s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,, 2 9 0 0 0 0 1
without recurrence, without w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,(- 3 9 0 0 0 0 1
creased hemoglobin creased c cr cre crea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 8 0 0 0 0 1
group); none group); g gr gro grou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 );- 3 9 0 0 0 0 1
tion. No tion. t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 .- 2 9 0 0 0 0 1
were reported. were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 2 0 0 0 0 1
One case one O On One One BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
treatment group: treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 :-- 3 8 0 0 0 0 1
upadacitinib-treated patient upadacitinib-treated u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 -(; 3 9 0 0 0 0 1
Supplement 2) supplement S Su Sup Supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 )-- 3 8 0 0 0 0 1
dupilumab-treated patient. dupilumab-treated d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 -. 2 9 0 0 0 0 1
thromboembolic events, thromboembolic t th thr thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 , 1 8 0 0 0 0 1
events, active events, e ev eve even BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,, 2 10 0 0 0 0 1
were reported were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 10 0 0 0 0 1
the end the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
in Supplement in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 . 1 2 0 0 0 0 1
Five nonserious five F Fi Fiv Five BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 9 0 0 0 0 1
the study-4 the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -- 2 9 0 0 0 0 1
umab group. umab u um uma umab BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 .- 2 9 0 0 0 0 1
dacitinib patients dacitinib d da dac daci BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 - 1 9 0 0 0 0 1
tion. Treatment tion. t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 . 1 10 0 0 0 0 1
patient or patient p pa pat pati BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 . 1 5 0 0 0 0 1
Discussion Discussion discussion D Di Dis Disc BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 10 0 0 0 0 1
To our to T To To To BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 ,- 2 9 0 0 0 0 1
paring upadacitinib paring p pa par pari BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 8 0 0 0 0 1
sixth clinical sixth s si six sixt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 . 1 10 0 0 0 0 1
This study this T Th Thi This BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 9 0 0 0 0 1
and all and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 ,- 2 9 0 0 0 0 1
ority of ority o or ori orit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 no 0 8 0 0 0 0 1
adults with adults a ad adu adul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 --.- 4 9 0 0 0 0 1
ferences between ferences f fe fer fere BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 no 0 8 0 0 0 0 1
rapidity of rapidity r ra rap rapi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 no 0 10 0 0 0 0 1
of skin of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 (,)., 5 8 0 0 0 0 1
upadacitinib-treated patients upadacitinib-treated u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 - 1 9 0 0 0 0 1
better results better b be bet bett BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 - 1 9 0 0 0 0 1
measures of measures m me mea meas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 3 . 1 9 0 0 0 0 1
generally safe generally g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 9 0 0 0 0 1
observed. observed. observed. o ob obs obse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 . 1 1 0 0 0 0 1
Despite the despite D De Des Desp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 , 1 8 0 0 0 0 1
remains an remains r re rem rema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 - 1 9 0 0 0 0 1
cacy outcomes, cacy c ca cac cacy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 ,, 2 8 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 --. 3 8 0 0 0 0 1
higher levels higher h hi hig high BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 9 0 0 0 0 1
improvements in improvements i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 -.- 3 9 0 0 0 0 1
tively high tively t ti tiv tive BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 no 0 9 0 0 0 0 1
Table 2. table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 . 1 10 0 1 0 0 1
End point end E En End End BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 no 0 3 0 0 0 0 1
Time point time T Ti Tim Time BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 no 0 3 0 0 0 0 1
Dupilumab, 300 dupilumab, D Du Dup Dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 6 ,() 3 9 0 0 0 0 1
Upadacitinib, 30 upadacitinib, U Up Upa Upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 6 ,() 3 10 0 0 0 0 1
Difference Difference difference D Di Dif Diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 no 0 3 0 0 0 0 1
P value p P P P P BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 6 no 0 2 0 0 0 0 1
Primary end primary P Pr Pri Prim BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 no 0 6 0 0 0 0 1
Achievement of achievement A Ac Ach Achi BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 no 0 10 0 0 0 0 1
EASI75 a easi75 E EA EAS EASI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 6 no 0 6 0 0 0 0 1
Week 16 week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 no 0 3 0 0 0 0 1
210 (61.1) 210 2 21 210 210 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 6 (.)[..] 7 10 0 0 0 0 1
247 (71.0) 247 2 24 247 247 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 6 (.)[..] 7 10 0 0 0 0 1
10 10 10 1 10 10 10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 6 no 0 1 0 0 0 0 1
.006 .006 .006 . .0 .00 .006 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 6 . 1 1 0 0 0 0 1
Secondary end secondary S Se Sec Seco BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
in order in i in in in BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 7 no 0 9 0 0 0 0 1
% Change % % % % % BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 7 no 0 7 0 0 0 0 1
baseline in baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
pruritus NRS pruritus p pr pru prur BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 7 no 0 8 0 0 0 0 1
Week 16 week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 2 0 0 0 0 1
−49.0 (2.0) −49.0 − −4 −49 −49. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 −.(.)[-.−.] 11 10 0 0 0 0 1
−66.9 (1.9) −66.9 − −6 −66 −66. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 −.(.)[-.−.] 11 10 0 0 0 0 1
−17.84 −17.84 −17.84 − −1 −17 −17. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 −. 2 2 0 0 0 0 1
<.001 <.001 <.001 < <. <.0 <.00 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 . 1 2 0 0 0 0 1
No. No. no. N No No. No. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 . 1 10 0 0 0 0 1
251 251 251 2 25 251 251 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
258 258 258 2 25 258 258 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
Achievement of achievement A Ac Ach Achi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
EASI100 a easi100 E EA EAS EASI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 no 0 6 0 0 0 0 1
Week 16 week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 3 0 0 0 0 1
26 (7.6) 26 2 26 26 26 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 7 (.)[..] 7 8 0 0 0 0 1
97 (27.9) 97 9 97 97 97 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 7 (.)[..] 7 10 0 0 0 0 1
20.3 20.3 20.3 2 20 20. 20.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 . 1 2 0 0 0 0 1
<.001 <.001 <.001 < <. <.0 <.00 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 . 1 2 0 0 0 0 1
Achievement of achievement A Ac Ach Achi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 10 0 0 0 0 1
EASI90 a easi90 E EA EAS EASI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 no 0 6 0 0 0 0 1
Week 16 week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 3 0 0 0 0 1
133 (38.7) 133 1 13 133 133 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 8 (.)[..] 7 10 0 0 0 0 1
211 (60.6) 211 2 21 211 211 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 8 (.)[..] 7 10 0 0 0 0 1
21.8 21.8 21.8 2 21 21. 21.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 . 1 1 0 0 0 0 1
<.001 <.001 <.001 < <. <.0 <.00 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 . 1 2 0 0 0 0 1
% Change % % % % % BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 8 no 0 7 0 0 0 0 1
baseline in baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 8 no 0 10 0 0 0 0 1
Pruritus NRS pruritus P Pr Pru Prur BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 no 0 8 0 0 0 0 1
Week 4 week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 2 0 0 0 0 1
−31.7 (2.2) −31.7 − −3 −31 −31. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 −.(.)[-.−.] 11 10 0 0 0 0 1
−59.5 (2.2) −59.5 − −5 −59 −59. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 −.(.)[-.−.] 11 10 0 0 0 0 1
−27.8 −27.8 −27.8 − −2 −27 −27. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 −. 2 2 0 0 0 0 1
<.001 <.001 <.001 < <. <.0 <.00 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 . 1 2 0 0 0 0 1
No. No. no. N No No. No. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 9 . 1 10 0 0 0 0 1
310 310 310 3 31 310 310 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
333 333 333 3 33 333 333 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
Achievement of achievement A Ac Ach Achi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
EASI75 a easi75 E EA EAS EASI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 no 0 6 0 0 0 0 1
Week 2 week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 9 no 0 2 0 0 0 0 1
60 (17.5) 60 6 60 60 60 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 9 (.)[..] 7 9 0 0 0 0 1
152 (43.7) 152 1 15 152 152 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 9 (.)[..] 7 10 0 0 0 0 1
26.0 26.0 26.0 2 26 26. 26.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 . 1 1 0 0 0 0 1
<.001 <.001 <.001 < <. <.0 <.00 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 . 1 2 0 0 0 0 1
% Change % % % % % BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 9 no 0 7 0 0 0 0 1
baseline in baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
Pruritus NRS pruritus P Pr Pru Prur BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 9 no 0 8 0 0 0 0 1
Week 1 week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 9 no 0 2 0 0 0 0 1
−8.8 (1.8) −8.8 − −8 −8. −8.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 −.(.)[-.−.] 11 9 0 0 0 0 1
−31.4 (1.7) −31.4 − −3 −31 −31. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 −.(.)[-.−.] 11 10 0 0 0 0 1
−22.7 −22.7 −22.7 − −2 −22 −22. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 −. 2 2 0 0 0 0 1
<.001 <.001 <.001 < <. <.0 <.00 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 . 1 2 0 0 0 0 1
No. No. no. N No No. No. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 . 1 10 0 0 0 0 1
327 327 327 3 32 327 327 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
337 337 337 3 33 337 337 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
Worst Pruritus worst W Wo Wor Wors BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
improvement ≥4 improvement i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 no 0 7 0 0 0 0 1
points a,c points p po poi poin BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 , 1 5 0 0 0 0 1
Week 16 week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 no 0 3 0 0 0 0 1
120 (35.7) 120 1 12 120 120 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.)[..] 7 10 0 0 0 0 1
188 (55.3) 188 1 18 188 188 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.)[..] 7 10 0 0 0 0 1
19.3 19.3 19.3 1 19 19. 19.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 10 . 1 1 0 0 0 0 1
<.001 <.001 <.001 < <. <.0 <.00 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 10 . 1 2 0 0 0 0 1
No. No. no. N No No. No. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 . 1 10 0 0 0 0 1
NA NA na N NA NA NA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 6 10 no 0 7 0 0 0 0 1
336 336 336 3 33 336 336 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
340 340 340 3 34 340 340 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
NA NA na N NA NA NA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 6 10 no 0 7 0 0 0 0 1
NA NA na N NA NA NA BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 6 10 no 0 7 0 0 0 0 1
Abbreviations: EASI75, abbreviations: A Ab Abb Abbr BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 :, 2 10 0 0 0 0 1
Index; NA, index; I In Ind Inde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 ;,;,. 5 7 0 0 0 0 1
a No. a a a a a BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 6 10 .()[]. 6 2 0 0 0 0 1
b Least-squares b b b b b BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 6 11 -()[]. 6 10 0 0 0 0 1
c Analyzed c c c c c BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 6 11 no 0 10 0 0 0 0 1
baseline. baseline. baseline. b ba bas base BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 11 . 1 1 0 0 0 0 1
Upadacitinib vs upadacitinib U Up Upa Upad BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 -- 2 10 0 1 0 0 0
Original Investigation original O Or Ori Orig BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 11 no 0 4 0 1 0 0 0
jamadermatology.com jamadermatology.com jamadermatology.com j ja jam jama BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 11 . 1 3 0 1 0 0 0
(Reprinted) JAMA (reprinted) ( (R (Re (Rep BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 11 (), 3 10 0 1 0 0 0
1051 1051 1051 1 10 105 1051 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 6 11 no 0 0 0 1 0 0 0
Downloaded From: downloaded D Do Dow Down BLOCKSTART PAGEEND NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 :://./// 8 10 0 1 1 0 0
achieving EASI90 achieving a ac ach achi BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 8 0 0 0 0 1
and elsewhere, and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,- 2 8 0 0 0 0 1
AD treatment ad A AD AD AD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 9 0 0 0 0 1
years with years y ye yea year BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
inflammatory skin inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,- 3 9 0 0 0 0 1
cess shifted cess c ce ces cess BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
Severity Index severity S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 ( 1 8 0 0 0 0 1
PASI100, respectively). pasi100, P PA PAS PASI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 ,). 3 9 0 0 0 0 1
psoriasis have psoriasis p ps pso psor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 , 1 8 0 0 0 0 1
scores PASI90 scores s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
systemic therapies, systemic s sy sys syst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 , 1 9 0 0 0 0 1
AD treatment ad A AD AD AD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 3 0 0 0 0 1
Treatment effect treatment T Tr Tre Trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 () 2 8 0 0 0 0 1
was also was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 - 1 8 0 0 0 0 1
pared with pared p pa par pare BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 .- 2 9 0 0 0 0 1
ment as ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
with upadacitinib, with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 10 0 0 0 0 1
meaningful improvements meaningful m me mea mean BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
week 1. week w we wee week BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 9 0 0 0 0 1
with a with w wi wit with BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 .-- 3 9 0 0 0 0 1
achieved significantly achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 no 0 8 0 0 0 0 1
improvement thresholds improvement i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 no 0 8 0 0 0 0 1
dupilumab. dupilumab. dupilumab. d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 2 . 1 1 0 0 0 0 1
Several key several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 2 no 0 7 0 0 0 0 1
pathogenesis of pathogenesis p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 2 ,-- 3 8 0 0 0 0 1
(epidermal barrier (epidermal ( (e (ep (epi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 2 (),-(- 6 8 0 0 0 0 1
liferation), IL-31 liferation), l li lif life BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 2 ),-(),-(- 9 9 0 0 0 0 1
nicity), and nicity), n ni nic nici BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 2 ),().,,- 8 10 0 0 0 0 1
gets the gets g ge get gets BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 --. 3 9 0 0 0 0 1
JAK1, upadacitinib jak1, J JA JAK JAK1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 2 , 1 9 0 0 0 0 1
proinflammatory mediators, proinflammatory p pr pro proi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 2 ,-,-,-,- 8 8 0 0 0 0 1
31, IFN-γ, 31, 3 31 31, 31, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 2 ,-,. 4 8 0 0 0 0 1
pathways may pathways p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 no 0 8 0 0 0 0 1
of upadacitinib of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 . 1 5 0 0 0 0 1
The safety the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 2 - 1 8 0 0 0 0 1
sistent with sistent s si sis sist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 2 no 0 8 0 0 0 0 1
phase 3 phase p ph pha phas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 (,, 3 8 0 0 0 0 1
Up), 8,9 up), U Up Up) Up), BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 2 ),,.- 5 9 0 0 0 0 1
Figure 2. figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 10 0 1 0 0 1
100 100 100 1 10 100 100 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
80 80 80 8 80 80 80 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
60 60 60 6 60 60 60 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
40 40 40 4 40 40 40 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
20 20 20 2 20 20 20 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
Proportion of proportion P Pr Pro Prop BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 , 1 10 0 0 0 0 1
Week Week week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
EASI75 EASI75 easi75 E EA EAS EASI BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 no 0 10 0 1 0 0 1
A A a A A A A BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 7 5 no 0 10 0 1 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
1 1 1 1 1 1 1 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
2 2 2 2 2 2 2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
4 4 4 4 4 4 4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
8 8 8 8 8 8 8 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
12 12 12 1 12 12 12 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
16 16 16 1 16 16 16 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
b b b b b b b BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
Upadacitinib (n upadacitinib U Up Upa Upad BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 6 () 2 10 0 0 0 0 1
Dupilumab (n dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 6 () 2 10 0 0 0 0 1
100 100 100 1 10 100 100 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
80 80 80 8 80 80 80 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
60 60 60 6 60 60 60 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
40 40 40 4 40 40 40 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
20 20 20 2 20 20 20 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
Proportion of proportion P Pr Pro Prop BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 6 , 1 10 0 0 0 0 1
Week Week week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
EASI90 EASI90 easi90 E EA EAS EASI BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 6 no 0 10 0 1 0 0 1
B B b B B B B BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 1 0 0 1
0 1 0 0 0 0 0 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
c c c c c c c BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
2 2 2 2 2 2 2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
4 4 4 4 4 4 4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
8 8 8 8 8 8 8 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 6 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
12 12 12 1 12 12 12 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
16 16 16 1 16 16 16 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
Upadacitinib (n upadacitinib U Up Upa Upad BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 7 () 2 10 0 0 0 0 1
Dupilumab (n dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 7 () 2 10 0 0 0 0 1
100 100 100 1 10 100 100 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
80 80 80 8 80 80 80 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
60 60 60 6 60 60 60 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
40 40 40 4 40 40 40 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
20 20 20 2 20 20 20 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
Proportion of proportion P Pr Pro Prop BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 7 , 1 10 0 0 0 0 1
Week Week week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
EASI100 EASI100 easi100 E EA EAS EASI BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
C C c C C C C BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
0 1 0 0 0 0 0 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
4 4 4 4 4 4 4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 7 no 0 3 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
8 8 8 8 8 8 8 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
12 12 12 1 12 12 12 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
16 16 16 1 16 16 16 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
Upadacitinib (n upadacitinib U Up Upa Upad BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 7 () 2 10 0 0 0 0 1
Dupilumab (n dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 8 () 2 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
-20 -20 -20 - -2 -20 -20 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 - 1 10 0 0 0 0 1
-40 -40 -40 - -4 -40 -40 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 - 1 10 0 0 0 0 1
-60 -60 -60 - -6 -60 -60 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 - 1 10 0 0 0 0 1
-80 -80 -80 - -8 -80 -80 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 - 1 10 0 0 0 0 1
-100 -100 -100 - -1 -10 -100 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 - 1 10 0 0 0 0 1
Change from change C Ch Cha Chan BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 8 , 1 10 0 0 0 0 1
Week Week week W We Wee Week BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
Worst pruritus worst W Wo Wor Wors BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
D D d D D D D BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
2 2 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
4 4 4 4 4 4 4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
6 6 6 6 6 6 6 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
8 8 8 8 8 8 8 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
12 12 12 1 12 12 12 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
10 10 10 1 10 10 10 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
14 14 14 1 14 14 14 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
a a a a a a a BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
16 16 16 1 16 16 16 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 9 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 9 no 0 0 0 0 0 0 1
Upadacitinib (n upadacitinib U Up Upa Upad BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 9 () 2 10 0 0 0 0 1
Dupilumab (n dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 9 () 2 10 0 0 0 0 1
A, Proportion a, A A, A, A, BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 , 1 8 0 0 0 0 1
Severity Index severity S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 (), 3 9 0 0 0 0 1
in EASI in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 9 (). 3 9 0 0 0 0 1
EASI (EASI100). easi E EA EAS EASI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 9 ()., 4 9 0 0 0 0 1
Scale (NRS) scale S Sc Sca Scal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 () 2 8 0 0 0 0 1
nonresponder imputation nonresponder n no non nonr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 9 no 0 9 0 0 0 0 1
data due data d da dat data BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 -.( 3 10 0 0 0 0 1
test distribution test t te tes test BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 10 no 0 9 0 0 0 0 1
missing data missing m mi mis miss BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 10 - 1 10 0 0 0 0 1
binomial distribution binomial b bi bin bino BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 10 -). 3 9 0 0 0 0 1
a P a a a a a BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 10 .. 2 1 0 0 0 0 1
b P b b b b b BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 7 11 .. 2 10 0 0 0 0 1
c P c c c c c BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 7 11 .. 2 10 0 0 0 0 1
Research Original research R Re Res Rese BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 11 no 0 4 0 1 0 0 0
Upadacitinib vs upadacitinib U Up Upa Upad BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 11 -- 2 10 0 1 0 0 0
1052 1052 1052 1 10 105 1052 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 7 11 no 0 0 0 1 0 0 0
JAMA Dermatology jama J JA JAM JAMA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 7 11 ,() 3 10 0 1 0 0 0
jamadermatology.com jamadermatology.com jamadermatology.com j ja jam jama BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 11 . 1 3 0 1 0 0 0
Downloaded From: downloaded D Do Dow Down BLOCKSTART PAGEEND NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 11 :://./// 8 10 0 1 1 0 0
vious studies vious v vi vio viou BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
arthritis, higher arthritis, a ar art arth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,- 2 10 0 0 0 0 1
dacitinib in dacitinib d da dac daci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ., 2 9 0 0 0 0 1
among the among a am amo amon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
inhibitors in inhibitors i in inh inhi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 (); 3 9 0 0 0 0 1
underlying this underlying u un und unde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 .-- 3 10 0 0 0 0 1
continuation secondary continuation c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
upadacitinib. Rates upadacitinib. u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 .,, 3 9 0 0 0 0 1
herpes zoster, herpes h he her herp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ,-- 3 9 0 0 0 0 1
cally higher cally c ca cal call BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 7 0 ,- 2 9 0 0 0 0 1
tivitis and tivitis t ti tiv tivi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 - 1 9 0 0 0 0 1
with dupilumab. with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ., 2 8 0 0 0 0 1
adverse cardiovascular adverse a ad adv adve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,- 2 9 0 0 0 0 1
tions were tions t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ., 2 9 0 0 0 0 1
observations were observations o ob obs obse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
of each of o of of of BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 2 0 0 0 0 1
Limitations Limitations limitations L Li Lim Limi BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 10 0 0 0 0 1
This study this T Th Thi This BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 1 . 1 9 0 0 0 0 1
results through results r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 1 , 1 8 0 0 0 0 1
ranked secondary ranked r ra ran rank BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 .- 2 9 0 0 0 0 1
being collected being b be bei bein BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 -.- 3 9 0 0 0 0 1
though not though t th tho thou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 , 1 9 0 0 0 0 1
upadacitinib and upadacitinib u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 , 1 8 0 0 0 0 1
patients who patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
treated as treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 .- 2 10 0 0 0 0 1
world practice, world w wo wor worl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ,- 2 9 0 0 0 0 1
bination with bination b bi bin bina BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 ; 1 9 0 0 0 0 1
corticosteroids is corticosteroids c co cor cort BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 - 1 9 0 0 0 0 1
tinib for tinib t ti tin tini BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 . 1 2 0 0 0 0 1
To maintain to T To To To BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 1 , 1 8 0 0 0 0 1
upadacitinib and upadacitinib u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 - 1 8 0 0 0 0 1
panied by panied p pa pan pani BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 , 1 9 0 0 0 0 1
comparison against comparison c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
these treatments. these t th the thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 .,, 3 8 0 0 0 0 1
was given was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 , 1 8 0 0 0 0 1
of patients, of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ,, 2 8 0 0 0 0 1
compared with compared c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ,. 2 9 0 0 0 0 1
response rates response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 8 0 0 0 0 1
present study present p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
subsequent responder subsequent s su sub subs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ., 2 9 0 0 0 0 1
potential bias potential p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 - 1 9 0 0 0 0 1
dacitinib group; dacitinib d da dac daci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 ;-- 3 9 0 0 0 0 1
therapy studies, therapy t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ,,. 3 8 0 0 0 0 1
72.9% of 72.9% 7 72 72. 72.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 1 .,, 3 9 0 0 0 0 1
achieved EASI75 achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ,,. 3 9 0 0 0 0 1
and 13.3% and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 .,. 3 5 0 0 0 0 1
Conclusions Conclusions conclusions C Co Con Conc BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 4 no 0 10 0 0 0 0 1
Overall, upadacitinib overall, O Ov Ove Over BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 4 ,- 2 9 0 0 0 0 1
rior efficacy rior r ri rio rior BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 4 - 1 9 0 0 0 0 1
ment in ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 4 --. 3 8 0 0 0 0 1
achieved higher achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 no 0 10 0 0 0 0 1
more rapid more m mo mor more BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 . 1 9 0 0 0 0 1
effective treatment effective e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 -- 2 8 0 0 0 0 1
severe AD severe s se sev seve BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 . 1 9 0 0 0 0 1
Table 3. table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 . 1 10 0 1 0 0 1
1 Dose 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 5 no 0 5 0 1 0 0 1
TEAE TEAE teae T TE TEA TEAE BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 no 0 10 0 0 0 0 1
Patients, No. patients, P Pa Pat Pati BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 ,.() 4 10 0 0 0 0 1
Dupilumab, Dupilumab, dupilumab, D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 , 1 6 0 0 0 0 1
300 mg 300 3 30 300 300 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 () 2 10 0 0 0 0 1
Upadacitinib, Upadacitinib, upadacitinib, U Up Upa Upad BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 , 1 8 0 0 0 0 1
30 mg 30 3 30 30 30 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 () 2 10 0 0 0 0 1
AE AE ae A AE AE AE BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 no 0 2 0 0 0 0 1
216 (62.8) 216 2 21 216 216 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
249 (71.6) 249 2 24 249 249 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
AE with ae A AE AE AE BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 no 0 10 0 0 0 0 1
being drug-related being b be bei bein BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 - 1 6 0 0 0 0 1
122 (35.5) 122 1 12 122 122 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
153 (44.0) 153 1 15 153 153 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
Severe AE severe S Se Sev Seve BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 10 0 0 0 0 1
14 (4.1) 14 1 14 14 14 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 (.) 3 9 0 0 0 0 1
25 (7.2) 25 2 25 25 25 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 (.) 3 9 0 0 0 0 1
SAE SAE sae S SA SAE SAE BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 no 0 4 0 0 0 0 1
4 (1.2) 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 (.) 3 8 0 0 0 0 1
10 (2.9) 10 1 10 10 10 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
SAE with sae S SA SAE SAE BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 no 0 10 0 0 0 0 1
of being of o of of of BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 7 0 0 0 0 1
2 (0.6) 2 2 2 2 2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
4 (1.1) 4 4 4 4 4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
AE leading ae A AE AE AE BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
study drug study s st stu stud BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 3 0 0 0 0 1
4 (1.2) 4 4 4 4 4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 10 0 0 0 0 1
7 (2.0) 7 7 7 7 7 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 10 0 0 0 0 1
AE leading ae A AE AE AE BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 no 0 0 0 0 0 0 1
1 (0.3) 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 3 0 0 0 0 1
AEs of aes A AE AEs AEs BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
Serious infections serious S Se Ser Seri BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
2 (0.6) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 4 0 0 0 0 1
4 (1.1) 4 4 4 4 4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 4 0 0 0 0 1
Opportunistic infection, opportunistic O Op Opp Oppo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 7 , 1 9 0 0 0 0 1
excluding tuberculosis excluding e ex exc excl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
herpes zoster herpes h he her herp BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 7 no 0 5 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 no 0 2 0 0 0 0 1
1 (0.3) 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 10 0 0 0 0 1
Herpes zoster herpes H He Her Herp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
3 (0.9) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 5 0 0 0 0 1
7 (2.0) 7 7 7 7 7 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 5 0 0 0 0 1
Active tuberculosis active A Ac Act Acti BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 no 0 1 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 no 0 1 0 0 0 0 1
Nonmelanoma skin nonmelanoma N No Non Nonm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
1 (0.3) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 3 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 no 0 0 0 0 0 0 1
Malignant neoplasm, malignant M Ma Mal Mali BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 8 , 1 10 0 0 0 0 1
NMSC NMSC nmsc N NM NMS NMSC BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 1 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
Lymphoma Lymphoma lymphoma L Ly Lym Lymp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 no 0 2 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 no 0 2 0 0 0 0 1
Hepatic disorder hepatic H He Hep Hepa BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
4 (1.2) 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 4 0 0 0 0 1
10 (2.9) 10 1 10 10 10 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 8 (.) 3 4 0 0 0 0 1
Adjudicated gastrointestinal adjudicated A Ad Adj Adju BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
perforations perforations perforations p pe per perf BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 8 no 0 4 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
Anemia Anemia anemia A An Ane Anem BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 8 no 0 8 0 0 0 0 1
1 (0.3) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 10 0 0 0 0 1
7 (2.0) 7 7 7 7 7 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 10 0 0 0 0 1
Neutropenia Neutropenia neutropenia N Ne Neu Neut BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
2 (0.6) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 6 0 0 0 0 1
6 (1.7) 6 6 6 6 6 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 6 0 0 0 0 1
Lymphopenia Lymphopenia lymphopenia L Ly Lym Lymp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 no 0 1 0 0 0 0 1
2 (0.6) 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 6 0 0 0 0 1
Creatine phosphokinase creatine C Cr Cre Crea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
elevation elevation elevation e el ele elev BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 8 no 0 4 0 0 0 0 1
10 (2.9) 10 1 10 10 10 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 8 (.) 3 10 0 0 0 0 1
23 (6.6) 23 2 23 23 23 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 8 (.) 3 10 0 0 0 0 1
Renal dysfunction renal R Re Ren Rena BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
1 (0.3) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 4 0 0 0 0 1
1 (0.3) 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 4 0 0 0 0 1
Adjudicated major adjudicated A Ad Adj Adju BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
cardiovascular events cardiovascular c ca car card BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 8 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
Adjudicated venous adjudicated A Ad Adj Adju BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 9 no 0 8 0 0 0 0 1
thromboembolic events thromboembolic t th thr thro BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
TEAEs reported teaes T TE TEA TEAE BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
treatment group treatment t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 9 no 0 5 0 0 0 0 1
Acne f acne A Ac Acn Acne BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 9 no 0 7 0 0 0 0 1
9 (2.6) 9 9 9 9 9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 (.) 3 8 0 0 0 0 1
55 (15.8) 55 5 55 55 55 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 9 (.) 3 10 0 0 0 0 1
Dermatitis atopic dermatitis D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
29 (8.4) 29 2 29 29 29 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 9 (.) 3 5 0 0 0 0 1
24 (6.9) 24 2 24 24 24 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 9 (.) 3 5 0 0 0 0 1
Upper respiratory upper U Up Upp Uppe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 9 (.) 3 10 0 0 0 0 1
22 (6.3) 22 2 22 22 22 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 9 (.) 3 2 0 0 0 0 1
Blood CPK blood B Bl Blo Bloo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
10 (2.9) 10 1 10 10 10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 9 (.) 3 3 0 0 0 0 1
23 (6.6) 23 2 23 23 23 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 9 (.) 3 3 0 0 0 0 1
Nasopharyngitis Nasopharyngitis nasopharyngitis N Na Nas Naso BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
22 (6.4) 22 2 22 22 22 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 9 (.) 3 5 0 0 0 0 1
20 (5.7) 20 2 20 20 20 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 9 (.) 3 5 0 0 0 0 1
Headache Headache headache H He Hea Head BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
21 (6.1) 21 2 21 21 21 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 9 (.) 3 10 0 0 0 0 1
14 (4.0) 14 1 14 14 14 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 9 (.) 3 10 0 0 0 0 1
Conjunctivitis Conjunctivitis conjunctivitis C Co Con Conj BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 10 no 0 10 0 0 0 0 1
29 (8.4) 29 2 29 29 29 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 10 (.) 3 6 0 0 0 0 1
5 (1.4) 5 5 5 5 5 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 (.) 3 5 0 0 0 0 1
Abbreviations: AE, abbreviations: A Ab Abb Abbr BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 10 :,;,; 5 9 0 0 0 0 1
NMSC, nonmelanoma nmsc, N NM NMS NMSC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 10 ,;,;,; 6 10 0 0 0 0 1
TEAE, treatment-emergent teae, T TE TEA TEAE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 10 ,-. 3 6 0 0 0 0 1
a As a a a a a BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 8 10 . 1 4 0 0 0 0 1
b A b b b b b BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 9 10 -- 2 10 0 0 0 0 1
A was a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 9 10 . 1 6 0 0 0 0 1
c All c c c c c BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 9 10 . 1 7 0 0 0 0 1
d Keratoacanthoma, d d d d d BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 9 10 , 1 10 0 0 0 0 1
according to according a ac acc acco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 10 . 1 4 0 0 0 0 1
e Hepatic e e e e e BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 9 10 :. 2 8 0 0 0 0 1
f Most f f f f f BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 9 11 ,, 2 10 0 1 0 0 1
comedones, involving comedones, c co com come BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 11 ,.. 3 9 0 1 0 0 1
treatment discontinuation. treatment t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 11 . 1 3 0 1 0 0 1
Upadacitinib vs upadacitinib U Up Upa Upad BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 11 -- 2 10 0 1 0 0 0
Original Investigation original O Or Ori Orig BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 11 no 0 4 0 1 0 0 0
jamadermatology.com jamadermatology.com jamadermatology.com j ja jam jama BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 11 . 1 3 0 1 0 0 0
(Reprinted) JAMA (reprinted) ( (R (Re (Rep BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 11 (), 3 10 0 1 0 0 0
1053 1053 1053 1 10 105 1053 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 9 11 no 0 0 0 1 0 0 0
Downloaded From: downloaded D Do Dow Down BLOCKSTART PAGEEND NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 11 :://./// 8 10 0 1 1 0 0
ARTICLE INFORMATION article A AR ART ARTI BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 10 0 1 0 0 1
Accepted for accepted A Ac Acc Acce BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 :,. 3 10 0 0 0 0 1
Published Online: published P Pu Pub Publ BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 :,. 3 9 0 0 0 0 1
doi:10.1001/jamadermatol.2021.3023 doi:10.1001/jamadermatol.2021.3023 doi:10.1001/jamadermatol.2021.3023 d do doi doi: BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 :./.. 5 10 0 0 0 0 1
Correction: This correction: C Co Cor Corr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 : 1 9 0 0 0 0 1
15, 2021, 15, 1 15 15, 15, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 ,, 2 10 0 0 0 0 1
week 24 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 8 0 0 0 0 1
data to data d da dat data BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 6 0 0 0 0 1
Open Access: open O Op Ope Open BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 : 1 9 0 0 0 0 1
distributed under distributed d di dis dist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 --- 3 10 0 0 0 0 1
License. © license. L Li Lic Lice BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 .. 2 8 0 0 0 0 1
Dermatology. Dermatology. dermatology. D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 2 0 0 0 0 1
Author Affiliations: author A Au Aut Auth BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 : 1 8 0 0 0 0 1
Center, Portland center, C Ce Cen Cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,();, 5 8 0 0 0 0 1
Chicago, Illinois chicago, C Ch Chi Chic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,(,,,,, 7 10 0 0 0 0 1
Chu); Department chu); C Ch Chu Chu) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 );, 3 8 0 0 0 0 1
& Science & & & & & BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 9 0 ,(); 4 7 0 0 0 0 1
Dermatology Unit, dermatology D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 , 1 7 0 0 0 0 1
Sciences, Humanitas sciences, S Sc Sci Scie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,,, 3 8 0 0 0 0 1
Italy (Costanzo); italy I It Ita Ital BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 (); 3 9 0 0 0 0 1
Center, Scientific center, C Ce Cen Cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 7 0 0 0 0 1
Hospitalization and hospitalization H Ho Hos Hosp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 8 0 0 0 0 1
(Costanzo); Department (costanzo); ( (C (Co (Cos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 (); 3 7 0 0 0 0 1
Allergology, University allergology, A Al All Alle BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,, 2 8 0 0 0 0 1
Utrecht, the utrecht, U Ut Utr Utre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,(-); 5 8 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 8 0 0 0 0 1
Centre Hospitalier centre C Ce Cen Cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 9 0 ,, 2 9 0 0 0 0 1
France (Barbarot); france F Fr Fra Fran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 0 ();, 4 8 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 8 0 0 0 0 1
Calgary, Alberta, calgary, C Ca Cal Calg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,(); 5 9 0 0 0 0 1
Community Pediatrics, community C Co Com Comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 8 0 0 0 0 1
University of university U Un Uni Univ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 7 0 0 0 0 1
(Prajapati); Division (prajapati); ( (P (Pr (Pra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ();, 4 9 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 9 0 0 0 0 1
Calgary, Alberta, calgary, C Ca Cal Calg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,(); 5 9 0 0 0 0 1
Wellness Centre, wellness W We Wel Well BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,, 3 7 0 0 0 0 1
(Prajapati); Dermatology (prajapati); ( (P (Pr (Pra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ();, 4 8 0 0 0 0 1
Calgary, Alberta, calgary, C Ca Cal Calg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,(); 5 8 0 0 0 0 1
Medical Research, medical M Me Med Medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,,, 3 7 0 0 0 0 1
(Prajapati); Department (prajapati); ( (P (Pr (Pra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ();, 4 9 0 0 0 0 1
School of school S Sc Sch Scho BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 8 0 0 0 0 1
Chicago, Illinois chicago, C Ch Chi Chic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,(); 4 8 0 0 0 0 1
Associates of associates A As Ass Asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 9 0 ,,(); 5 8 0 0 0 0 1
Karolinska Institutet karolinska K Ka Kar Karo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 8 0 0 0 0 1
Hospital, Stockholm, hospital, H Ho Hos Hosp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,,(); 5 7 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 , 1 9 0 0 0 0 1
University of university U Un Uni Univ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,,(). 5 9 0 0 0 0 1
Author Contributions: author A Au Aut Auth BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 : 1 9 0 0 0 0 1
full access full f fu ful full BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 no 0 9 0 0 0 0 1
responsibility for responsibility r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 no 0 9 0 0 0 0 1
accuracy of accuracy a ac acc accu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 . 1 5 0 0 0 0 1
Concept and concept C Co Con Conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 :,,,. 5 9 0 0 0 0 1
Acquisition, analysis, acquisition, A Ac Acq Acqu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 ,,: 3 10 0 0 0 0 1
authors. authors. authors. a au aut auth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 . 1 1 0 0 0 0 1
Drafting of drafting D Dr Dra Draf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 :,,, 4 9 0 0 0 0 1
Liu, Ladizinski, liu, L Li Liu Liu, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 2 ,,. 3 4 0 0 0 0 1
Critical revision critical C Cr Cri Crit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 no 0 9 0 0 0 0 1
intellectual content: intellectual i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 :. 2 6 0 0 0 0 1
Statistical analysis: statistical S St Sta Stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 :,,. 4 7 0 0 0 0 1
Obtained funding: obtained O Ob Obt Obta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 :,. 3 6 0 0 0 0 1
Administrative, technical, administrative, A Ad Adm Admi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 ,,: 3 8 0 0 0 0 1
Teixeira, Simpson, teixeira, T Te Tei Teix BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 2 ,,,. 4 6 0 0 0 0 1
Supervision: Blauvelt, supervision: S Su Sup Supe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 :,,-, 5 9 0 0 0 0 1
Barbarot, Prajapati, barbarot, B Ba Bar Barb BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 2 ,,,. 4 6 0 0 0 0 1
Conflict of conflict C Co Con Conf BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 : 1 9 0 0 0 0 1
reported receiving reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 7 0 0 0 0 1
reimbursement for reimbursement r re rei reim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 3 no 0 10 0 0 0 0 1
AbbVie and abbvie A Ab Abb AbbV BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ; 1 8 0 0 0 0 1
Sanofi during sanofi S Sa San Sano BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ; 1 10 0 0 0 0 1
as a as a as as as BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 / 1 8 0 0 0 0 1
investigator for investigator i in inv inve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ,,,, 4 9 0 0 0 0 1
Arcutis, Arena, arcutis, A Ar Arc Arcu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,, 4 7 0 0 0 0 1
Ingelheim, Bristol ingelheim, I In Ing Inge BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,, 3 8 0 0 0 0 1
Lilly and lilly L Li Lil Lill BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 3 ,,,, 4 8 0 0 0 0 1
Incyte, Janssen, incyte, I In Inc Incy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,,,,, 7 10 0 0 0 0 1
Sun Pharma, sun S Su Sun Sun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 9 3 ,.,, 4 8 0 0 0 0 1
Wu, Liu, wu, W Wu Wu, Wu, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,- 4 7 0 0 0 0 1
employees of employees e em emp empl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 , 1 8 0 0 0 0 1
stock and/or stock s st sto stoc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 3 /. 2 8 0 0 0 0 1
receiving grants receiving r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 3 ,,, 3 8 0 0 0 0 1
Incyte, Kyowa incyte, I In Inc Incy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,, 3 8 0 0 0 0 1
Merck, Novartis, merck, M Me Mer Merc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,,,, 6 9 0 0 0 0 1
and Vanda; and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ;,, 3 8 0 0 0 0 1
Arena, BenevolentAI arena, A Ar Are Aren BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 ,,, 3 8 0 0 0 0 1
Bluefin Biomedicine bluefin B Bl Blu Blue BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,, 2 8 0 0 0 0 1
Boston Consulting boston B Bo Bos Bost BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 3 , 1 8 0 0 0 0 1
(CA), Coronado, (ca), ( (C (CA (CA) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 (),,,,, 7 8 0 0 0 0 1
ExcerptaMedica, Forte excerptamedica, E Ex Exc Exce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,, 4 8 0 0 0 0 1
Kyowa Kirin kyowa K Ky Kyo Kyow BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 , 1 8 0 0 0 0 1
Pharm, Medscape pharm, P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,, 3 6 0 0 0 0 1
Dermatologics, Pfizer, dermatologics, D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,, 2 7 0 0 0 0 1
Cosmetique, Regeneron, cosmetique, C Co Cos Cosm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,, 4 8 0 0 0 0 1
SPARC India, sparc S SP SPA SPAR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 , 1 8 0 0 0 0 1
work. Dr work. w wo wor work BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 . 1 9 0 0 0 0 1
AbbVie during abbvie A Ab Abb AbbV BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ; 1 8 0 0 0 0 1
from Novartis from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ; 1 8 0 0 0 0 1
from Janssen, from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ,,, 3 9 0 0 0 0 1
submitted work. submitted s su sub subm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 .- 2 8 0 0 0 0 1
receiving grants receiving r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 3 , 1 8 0 0 0 0 1
advisory board advisory a ad adv advi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ,; 2 9 0 0 0 0 1
serving as serving s se ser serv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ; 1 9 0 0 0 0 1
serving as serving s se ser serv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ; 1 8 0 0 0 0 1
serving as serving s se ser serv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ; 1 8 0 0 0 0 1
serving as serving s se ser serv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 8 0 0 0 0 1
for Galderma; for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ; 1 9 0 0 0 0 1
for Janssen; for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ;, 2 9 0 0 0 0 1
member, and member, m me mem memb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ,; 2 9 0 0 0 0 1
Lilly, Leo lilly, L Li Lil Lill BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,, 3 9 0 0 0 0 1
outside the outside o ou out outs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 . 1 9 0 0 0 0 1
receiving grants receiving r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 3 ; 1 9 0 0 0 0 1
from Sanofi, from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ,,,,, 5 9 0 0 0 0 1
Pfizer, UCB, pfizer, P Pf Pfi Pfiz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,, 2 9 0 0 0 0 1
study. Dr study. s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 . 1 9 0 0 0 0 1
from AbbVie, from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ,,,,, 5 9 0 0 0 0 1
Arcutis, Aspen, arcutis, A Ar Arc Arcu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,, 3 7 0 0 0 0 1
Ingelheim, Bristol ingelheim, I In Ing Inge BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,, 4 9 0 0 0 0 1
Concert, Dermira, concert, C Co Con Conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 ,,,, 4 7 0 0 0 0 1
GlaxoSmithKline, Homeocan, glaxosmithkline, G Gl Gla Glax BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,, 4 8 0 0 0 0 1
Pharma, Medexus, pharma, P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,,, 5 8 0 0 0 0 1
Regeneron, Sanofi regeneron, R Re Reg Rege BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,, 4 8 0 0 0 0 1
UCB, and ucb, U UC UCB UCB, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,. 2 8 0 0 0 0 1
Lio reported lio L Li Lio Lio BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 , 1 8 0 0 0 0 1
Regeneron/Sanofi Genzyme, regeneron/sanofi R Re Reg Rege BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 /,; 3 8 0 0 0 0 1
fees from fees f fe fee fees BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 /,,, 4 9 0 0 0 0 1
Pfizer, Galderma, pfizer, P Pf Pfi Pfiz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,',, 5 9 0 0 0 0 1
Advisory board, advisory A Ad Adv Advi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 ,,, 3 8 0 0 0 0 1
Therapeutics, IntraDerm, therapeutics, T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,, 4 7 0 0 0 0 1
Arbonne, and arbonne, A Ar Arb Arbo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,; 2 8 0 0 0 0 1
and; other and; a an and and; BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ; 1 8 0 0 0 0 1
Theraplex; in theraplex; T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ;, 2 8 0 0 0 0 1
Theraplex AIM theraplex T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 no 0 8 0 0 0 0 1
company. Dr company. c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 . 1 9 0 0 0 0 1
from AbbVie from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ; 1 9 0 0 0 0 1
personal fees personal p pe per pers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 8 0 0 0 0 1
work. Dr work. w wo wor work BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 . 1 8 0 0 0 0 1
personal fees personal p pe per pers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 8 0 0 0 0 1
the study; the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ;,,, 4 9 0 0 0 0 1
Leo, Janssen, leo, L Le Leo Leo, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ,,,,; 5 9 0 0 0 0 1
from Lilly, from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ,,,, 4 9 0 0 0 0 1
the submitted the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 . 1 8 0 0 0 0 1
reported. reported. reported. r re rep repo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 . 1 1 0 0 0 0 1
Funding/Support: AbbVie funding/support: F Fu Fun Fund BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 7 /: 2 9 0 0 0 0 1
these studies these t th the thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 no 0 10 0 0 0 0 1
manuscript. manuscript. manuscript. m ma man manu BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 . 1 2 0 0 0 0 1
Role of role R Ro Rol Role BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 7 /: 2 7 0 0 0 0 1
participated in participated p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 ;; 2 9 0 0 0 0 1
collection, analysis, collection, c co col coll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 ,,; 3 10 0 0 0 0 1
writing, reviewing, writing, w wr wri writ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 ,, 2 9 0 0 0 0 1
for submission. for f fo for for BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 . 1 2 0 0 0 0 1
Data Sharing data D Da Dat Data BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 8 :. 2 10 0 0 0 0 1
Additional Information: additional A Ad Add Addi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 8 : 1 8 0 0 0 0 1
thank all thank t th tha than BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 no 0 10 0 0 0 0 1
and the and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 . 1 9 0 0 0 0 1
Priya S. priya P Pr Pri Priy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 8 .,,, 4 8 0 0 0 0 1
writing support writing w wr wri writ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 ; 1 9 0 0 0 0 1
she was she s sh she she BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 - 1 8 0 0 0 0 1
AbbVie Inc. abbvie A Ab Abb AbbV BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 8 . 1 2 0 0 0 0 1
REFERENCES REFERENCES references R RE REF REFE BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 10 8 no 0 10 0 0 0 0 1
1. Weidinger 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,,,, 5 9 0 0 0 0 1
Irvine AD. irvine I Ir Irv Irvi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 10 8 ... 3 10 0 0 0 0 1
2018;4(1):1. doi:10.1038/s41572-018-0001-z 2018;4(1):1. 2 20 201 2018 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 8 ;():.:./--- 11 8 0 0 0 0 1
2. Langan 2. 2 2. 2. 2. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,,. 4 10 0 0 0 0 1
dermatitis. Lancet. dermatitis. d de der derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 ..;():-. 8 10 0 0 0 0 1
doi:10.1016/S0140-6736(20)31286-1 doi:10.1016/S0140-6736(20)31286-1 doi:10.1016/s0140-6736(20)31286-1 d do doi doi: BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 8 :./-()- 7 7 0 0 0 0 1
3. Howell 3. 3 3. 3. 3. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 .,,. 4 9 0 0 0 0 1
Janus kinase janus J Ja Jan Janu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 10 9 . 1 10 0 0 0 0 1
Front Immunol. front F Fr Fro Fron BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 9 .;:.:./ 7 8 0 0 0 0 1
fimmu.2019.02342 fimmu.2019.02342 fimmu.2019.02342 f fi fim fimm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 9 .. 2 3 0 0 0 0 1
4. He 4. 4 4. 4. 4. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 .,-. 4 9 0 0 0 0 1
atopic dermatitis: atopic a at ato atop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 9 :.. 3 10 0 0 0 0 1
2019;20(2):181-192. doi:10.1007/ 2019;20(2):181-192. 2 20 201 2019 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 9 ;():-.:./ 9 6 0 0 0 0 1
s40257-018-0413-2 s40257-018-0413-2 s40257-018-0413-2 s s4 s40 s402 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 --- 3 3 0 0 0 0 1
5. Simpson 5. 5 5. 5. 5. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 .,,-,; 6 9 0 0 0 0 1
SOLO 1 solo S SO SOL SOLO BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 10 9 . 1 10 0 0 0 0 1
of dupilumab of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 9 . 1 9 0 0 0 0 1
N Engl n N N N N BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 10 9 .;():-.:. 9 8 0 0 0 0 1
1056/NEJMoa1610020 1056/NEJMoa1610020 1056/nejmoa1610020 1 10 105 1056 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 9 / 1 3 0 0 0 0 1
6. Parmentier 6. 6 6. 6. 6. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 .,,,. 5 10 0 0 0 0 1
in vivo in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 9 no 0 9 0 0 0 0 1
upadacitinib (ABT-494). upadacitinib u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 9 (-)..;:. 8 9 0 0 0 0 1
doi:10.1186/s41927-018-0031-x doi:10.1186/s41927-018-0031-x doi:10.1186/s41927-018-0031-x d do doi doi: BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 9 :./--- 6 5 0 0 0 0 1
7. Guttman-Yassky 7. 7 7. 7. 7. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .-,,,. 6 9 0 0 0 0 1
Upadacitinib in upadacitinib U Up Upa Upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 10 no 0 8 0 0 0 0 1
atopic dermatitis: atopic a at ato atop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 :- 2 7 0 0 0 0 1
randomized, placebo-controlled randomized, r ra ran rand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 ,-. 3 10 0 0 0 0 1
Immunol. 2020;145(3):877-884. immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 10 .;():-.:./ 10 8 0 0 0 0 1
j.jaci.2019.11.025 j.jaci.2019.11.025 j.jaci.2019.11.025 j j. j.j j.ja BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 10 .... 4 3 0 0 0 0 1
8. Guttman-Yassky 8. 8 8. 8. 8. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .-,,, 5 8 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 .- 2 9 0 0 0 0 1
adolescents and adolescents a ad ado adol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 10 -- 2 9 0 0 0 0 1
atopic dermatitis atopic a at ato atop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 (): 3 9 0 0 0 0 1
results from results r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 11 10 -, 2 7 0 0 0 0 1
randomised controlled randomised r ra ran rand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 ..; 3 10 0 0 0 0 1
397(10290):2151-2168. doi:10.1016/ 397(10290):2151-2168. 3 39 397 397( BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 10 ():-.:./ 8 6 0 0 0 0 1
S0140-6736(21)00588-2 S0140-6736(21)00588-2 s0140-6736(21)00588-2 S S0 S01 S014 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 -()- 4 4 0 0 0 0 1
9. Reich 9. 9 9. 9. 9. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 .,,-,. 6 9 0 0 0 0 1
Safety and safety S Sa Saf Safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 no 0 9 0 0 0 0 1
with topical with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 11 no 0 9 0 0 0 0 1
adults with adults a ad adu adul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 11 -- 2 9 0 0 0 0 1
(AD Up): (ad ( (A (AD (AD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 ():,-, 6 9 0 0 0 0 1
placebo-controlled, phase placebo-controlled, p pl pla plac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 11 -,..; 5 10 0 0 0 0 1
(10290):2169-2181. doi:10.1016/ (10290):2169-2181. ( (1 (10 (102 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 11 ():-.:./ 8 6 0 0 0 0 1
S0140-6736(21)00589-4 S0140-6736(21)00589-4 s0140-6736(21)00589-4 S S0 S01 S014 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 -()- 4 4 0 0 0 0 1
10. World 10. 1 10 10. 10. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 .. 2 9 0 1 0 0 1
Association Declaration association A As Ass Asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 : 1 9 0 1 0 0 1
principles for principles p pr pri prin BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 11 no 0 10 0 1 0 0 1
Research Original research R Re Res Rese BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 11 11 no 0 4 0 1 0 0 0
Upadacitinib vs upadacitinib U Up Upa Upad BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 -- 2 10 0 1 0 0 0
1054 1054 1054 1 10 105 1054 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 11 11 no 0 0 0 1 0 0 0
JAMA Dermatology jama J JA JAM JAMA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 11 11 ,() 3 10 0 1 0 0 0
jamadermatology.com jamadermatology.com jamadermatology.com j ja jam jama BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 11 . 1 3 0 1 0 0 0
Downloaded From: downloaded D Do Dow Down BLOCKSTART PAGEEND NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 :://./// 8 10 0 1 1 0 0
subjects. JAMA. subjects. s su sub subj BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 ..;():-.:. 10 10 0 1 0 0 1
1001/jama.2013.281053 1001/jama.2013.281053 1001/jama.2013.281053 1 10 100 1001 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 0 /.. 3 4 0 1 0 0 1
11. Hanifin 11. 1 11 11. 11. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,. 3 9 0 0 0 0 1
atopic dermatitis. atopic a at ato atop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 .(). 4 10 0 0 0 0 1
1980;60(92):44-47. 1980;60(92):44-47. 1980;60(92):44-47. 1 19 198 1980 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 0 ;():-. 6 3 0 0 0 0 1
12. Silverberg 12. 1 12 12. 12. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,,,. 5 10 0 0 0 0 1
best endpoints best b be bes best BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 no 0 8 0 0 0 0 1
and Scoring and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 ? 1 9 0 0 0 0 1
prospective observational prospective p pr pro pros BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 .. 2 8 0 0 0 0 1
2021;184(5):888-895. doi:10.1111/bjd.19457 2021;184(5):888-895. 2 20 202 2021 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 0 ;():-.:./. 10 7 0 0 0 0 1
13. Schmitt 13. 1 13 13. 13. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 2 .,,,. 5 8 0 0 0 0 1
Determinants of determinants D De Det Dete BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 2 no 0 10 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 2 .. 2 9 0 0 0 0 1
2008;6(6):458-465. doi:10.1111/j.1610-0387.2007. 2008;6(6):458-465. 2 20 200 2008 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 2 ;():-.:./.-.. 13 9 0 0 0 0 1
06609.x 06609.x 06609.x 0 06 066 0660 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 2 . 1 1 0 0 0 0 1
14. Silverberg 14. 1 14 14. 14. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 3 .,,,. 5 9 0 0 0 0 1
comprehensive conceptual comprehensive c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 no 0 7 0 0 0 0 1
experience of experience e ex exp expe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 . 1 9 0 0 0 0 1
Dermatol. 2018;19(5):759-769. dermatol. D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 3 .;():-.:./- 11 10 0 0 0 0 1
018-0381-6 018-0381-6 018-0381-6 0 01 018 018- BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 3 -- 2 2 0 0 0 0 1
15. Augustin 15. 1 15 15. 15. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 4 .,,,. 5 9 0 0 0 0 1
Characterizing treatment-related characterizing C Ch Cha Char BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 4 - 1 9 0 0 0 0 1
atopic eczema: atopic a at ato atop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 4 : 1 9 0 0 0 0 1
orientation. J orientation. o or ori orie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 4 ..; 3 10 0 0 0 0 1
(1):142-152. doi:10.1111/jdv.15919 (1):142-152. ( (1 (1) (1): BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 4 ():-.:./. 9 6 0 0 0 0 1
16. Leung 16. 1 16 16. 16. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,-. 4 9 0 0 0 0 1
complexities of complexities c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 : 1 8 0 0 0 0 1
paradigms in paradigms p pa par para BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 . 1 10 0 0 0 0 1
Immunol. 2014;134(4):769-779. immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 5 .;():-.:./.. 12 10 0 0 0 0 1
2014.08.008 2014.08.008 2014.08.008 2 20 201 2014 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 5 .. 2 2 0 0 0 0 1
17. Silverberg 17. 1 17 17. 17. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 9 0 0 0 0 1
Efficacy and efficacy E Ef Eff Effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 6 no 0 10 0 0 0 0 1
moderate-to-severe atopic moderate-to-severe m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 --: 3 7 0 0 0 0 1
a randomized a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 11 6 .. 2 8 0 0 0 0 1
2020;156(8):863-873. doi:10.1001/ 2020;156(8):863-873. 2 20 202 2020 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 6 ;():-.:./ 9 6 0 0 0 0 1
jamadermatol.2020.1406 jamadermatol.2020.1406 jamadermatol.2020.1406 j ja jam jama BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 6 .. 2 4 0 0 0 0 1
18. Simpson 18. 1 18 18. 18. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 7 .,,,. 5 10 0 0 0 0 1
and safety and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 7 no 0 9 0 0 0 0 1
with moderate-to-severe with w wi wit with BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 7 --( 3 8 0 0 0 0 1
MONO-1): a mono-1): M MO MON MONO BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 7 -):,-,, 7 9 0 0 0 0 1
placebo-controlled, phase placebo-controlled, p pl pla plac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 7 -,..; 5 10 0 0 0 0 1
(10246):255-266. doi:10.1016/ (10246):255-266. ( (1 (10 (102 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 7 ():-.:./ 8 5 0 0 0 0 1
S0140-6736(20)30732-7 S0140-6736(20)30732-7 s0140-6736(20)30732-7 S S0 S01 S014 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 7 -()- 4 4 0 0 0 0 1
19. Simpson 19. 1 19 19. 19. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 .,,,. 5 9 0 0 0 0 1
Baricitinib in baricitinib B Ba Bar Bari BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 8 -- 2 10 0 0 0 0 1
atopic dermatitis atopic a at ato atop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 8 no 0 9 0 0 0 0 1
topical corticosteroids: topical t to top topi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 8 : 1 8 0 0 0 0 1
randomized monotherapy randomized r ra ran rand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 8 . 1 9 0 0 0 0 1
Dermatol. 2020;183(2):242-255. dermatol. D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 8 .;():-.:./ 10 9 0 0 0 0 1
bjd.18898 bjd.18898 bjd.18898 b bj bjd bjd. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 8 . 1 2 0 0 0 0 1
20. Eichenfield 20. 2 20 20. 20. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 9 .,,,. 5 9 0 0 0 0 1
Guidelines of guidelines G Gu Gui Guid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 9 no 0 9 0 0 0 0 1
dermatitis, section dermatitis, d de der derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 9 ,: 2 9 0 0 0 0 1
of atopic of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 . 1 10 0 0 0 0 1
Acad Dermatol. acad A Ac Aca Acad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 9 .;():-.:./. 11 10 0 0 0 0 1
jaad.2014.03.023 jaad.2014.03.023 jaad.2014.03.023 j ja jaa jaad BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 9 ... 3 3 0 0 0 0 1
Upadacitinib vs upadacitinib U Up Upa Upad BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 -- 2 10 0 1 0 0 0
Original Investigation original O Or Ori Orig BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 no 0 4 0 1 0 0 0
jamadermatology.com jamadermatology.com jamadermatology.com j ja jam jama BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 11 . 1 3 0 1 0 0 0
(Reprinted) JAMA (reprinted) ( (R (Re (Rep BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 11 (), 3 10 0 1 0 0 0
1055 1055 1055 1 10 105 1055 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 11 11 no 0 0 0 1 0 0 0
Downloaded From: downloaded D Do Dow Down BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 :://./// 8 10 0 1 1 0 0

